|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||69.30 / 106.67|
The autoinjector will be free for insured patients and those whose annual income is less than $100,000.
We initiated one new position and trimmed/added to several others as December-quarter earnings season kicked off.
Sangamo Therapeutics, Impax Laboratories and Portola Pharmaceutical are among the premarket movers in biotech.
The drug maker's shares have fallen 6.2% since Wednesday's market open.
The price of EpiPens has surged about 25% annually since 2007.
Cigna will now encourage patients to use either Impax's or Mylan's generic autoinjector. Impax offers cheaper prices, but can its manufacturing keep up?
Generic epinephrine auto-injector from Impax Laboratories available at CVS Pharmacy at cash price 80% lower than EpiPen®
Shares of CVS have taken a hit over the past year, and while the company is doing what it can to stem the slide, it hasn't been enough.
The market continued its run as the new year started, with a number of portfolio positions showing nice advances.
The company's consistency is a testament to management’s commitment to and focus on continued cost improvements and self-help initiatives exclusive of the Rite Aid merger.
CVS has cash on hand and is benefiting from recent acquisitions.
As 2016 comes to a close, we have ample cash in the portfolio to take advantage of any near-term pullback in the market.
We used available cash to scale into 2 portfolio positions before the Christmas holiday.
We might have this one on the chopping block soon, so be ready for that alert should it come out.
With an assortment of last minute gift ideas, stocking stuffers and everyday essentials, CVS Pharmacy takes the stress out of holiday shopping and entertaining
During a week that brought the long-awaited Fed interest rate increase, we exited one portfolio position.
During the week, we downgraded one stock's rating and exited a position as indices showed mixed performance.
CVS Health is an example of using LEAP options to manufacture a great entry point.
Jim Cramer says stocks keep leapfrogging their peers in sectors like airlines and semiconductors.
The retail pharmacy and pharmacy benefit manager saw shares fall 1.7% ahead of market's open Thursday.
Company officials highlighted CVS' diversified lines of business as a way to manage political changes.
We believe 2017 will be another challenging year for CVS, and we expect the stock to remain rangebound.
We are watching this name closely to ensure fundamentals are sound.
More than 100 CVS Pharmacy locations in Nevada can now dispense naloxone
Still, the latest government data are largely favorable to the retail-related holdings in our portfolio.
Eli Lilly and Express Scripts are seeking to avoid potential bad press over high insulin prices.